Table S1 – Overall survival rates according to the study variables (in 5 years).

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **n** | **Overall Survival****Rates** **(% in 5 years)** | **P value****(\*1)** |
|  |  |  |  |
| **Histopathology**  |  |  |  |
| Squamous cells carcinoma | 110 | 74,0 | 0,432 |
| Adenocarcinoma/Adenosquamous | 9 | 87,5 |  |
|  |  |  |  |
| **Histological grade** |  |  |  |
| Grade I | 4 | 25,0 | 0,126 |
| Grade II | 50 | 59,2 |  |
| Grade III | 5 | 80,0 |  |
|  |  |  |  |
| **Type of carcinoma** |  |  |  |
| In situ | 50 | 100,0 | < 0,001 |
| Invasive | 69 | 58,9 |  |
|  |  |  |  |
| **Stage (FIGO)** |  |  |  |
| In situ | 50 | 100,0 | < 0,001 |
| Stage1 + 2 | 40 | 75,0 |  |
| Stage3 + 4  | 29 | 35,9 |  |
|  |  |  |  |
| **Lymph node metastasis (\*2)** |  |  |  |
| No  | 109 | 78,3 | 0,001 |
| Yes | 9 | 44,4 |  |
|  |  |  |  |
| **Elafin – plasm cell membrane** |  |  |  |
| Negative / 1+ | 66 | 74,4 | 0,974 |
| 2+ / 3+  | 53 | 75,8 |  |
|  |  |  |  |
| **Elafin – nucleus** |  |  |  |
| Negative / 1+ | 102 | 74,8 | 0,832 |
| 2+ / 3+  | 17 | 76,5 |  |
|  |  |  |  |
| **Elafin – cytoplasm** |  |  |  |
| Negative / 1+ | 97 | 75,7 | 0,663 |
| 2+ / 3+  | 22 | 71,8 |  |
|  |  |  |  |

(\*1) Log-rank test.

(\*2) Clinical or pathological assessment.

The International Federation of Gynecology and Obstetrics (FIGO)